EUVIMEDEUVIMED entdecken
Systematische ÜbersichtOpen Access

Biologic Therapies and Biomarkers in Severe Childhood Asthma: A Systematic Review of Omalizumab and Mepolizumab

Ana Beatriz Ferreira Gusmão iD, Breno Oliveira Marques iD, Ana Luiza Ferreira Gusmão iD, Raquel Teles de Lacerda iD, Ananda Pereira da França iD, Ellen Karoline da Silva iD, Gabrielle Silva Sousa iD, Maxuell Nunes Pereira

Pediatric Pulmonology · 2026-08 · 61 (8)

DOI: 10.1002/ppul.71756 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Pediatric Pulmonology, online erschienen am 27.07.2026. Verfasst von Ana Beatriz Ferreira Gusmão und 7 weiteren Autor:innen. Beteiligte Einrichtung: Instituto Multidisciplinar em Saúde da Universidade Federal da Bahia-IMS/UFBA, Vitória da Conquista, Brazil. Hauptthemen laut MEDLINE: Omalizumab, Asthma, Antibodies, Monoclonal, Humanized, Anti-Asthmatic Agents. Die Arbeit nennt 34 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Severe asthma in children is challenging to manage due to high exacerbation rates and significant impacts on quality of life. Despite corticosteroids and bronchodilators, many patients remain symptomatic, highlighting the need for alternative treatments. Biologic therapies, such as omalizumab and mepolizumab, offer potential to reduce exacerbations and oral corticosteroid use. This study aimed to evaluate the efficacy of novel biologic therapies in managing severe pediatric asthma.

Methods

A systematic review was conducted following the PRISMA protocol and registered on PROSPERO (CRD42025634956). Studies published between January 2019 and December 2024 were included. Eligible articles were randomized clinical trials, cohort, and case–control studies involving biologic therapies, excluding those with adults, animals, or unrelated topics. Data extraction was performed in Microsoft Excel, and bias was assessed using the Newcastle–Ottawa tool and the Jadad scale.

Results

Most trials analyzed omalizumab, with only one evaluating mepolizumab. These therapies significantly reduced asthma exacerbations, with effects sustained up to 6 years. Reductions in hospitalizations, PICU admissions, and ED visits were noted. Most studies used manufacturer‐recommended doses, while some adjusted doses based on weight and/or IgE levels. Pulmonary function improved in seven studies (increased FEV1), while three showed no significant changes. A reduction in inhaled and oral corticosteroid use, FeNO, and eosinophil levels was observed, suggesting reduced airway inflammation. Most patients tolerated therapies well, with mild adverse events reported.

Conclusion

Biologic therapies, particularly omalizumab, show promising clinical benefits for managing severe pediatric asthma. Further studies are needed to assess their long‐term safety and effectiveness.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

OmalizumabAsthmaAntibodies, Monoclonal, HumanizedAnti-Asthmatic AgentsBiological TherapyHumansChildBiomarkersSeverity of Illness IndexTreatment Outcome

Stichwörter der Autor:innen

asthmabiological therapychildomalizumabquality of life

Substanzen

OmalizumabAntibodies, Monoclonal, HumanizedmepolizumabAnti-Asthmatic AgentsBiomarkers

Autor:innen und Institutionen

  • Instituto Multidisciplinar em Saúde da Universidade Federal da Bahia-IMS/UFBA, Vitória da Conquista, Brazil.
  • Universidade Estadual da Bahia (UESB), Vitória da Conquista, Brazil.

ORCID-Profile: Ana Beatriz Ferreira Gusmão, Breno Oliveira Marques, Ana Luiza Ferreira Gusmão, Raquel Teles de Lacerda, Ananda Pereira da França, Ellen Karoline da Silva, Gabrielle Silva Sousa

Zitieren

APA

Gusmão, A. B. F., Marques, B. O., Gusmão, A. L. F., de Lacerda, R. T., França, A. P. D., Silva, E. K. D., Sousa, G. S., & Pereira, M. N. (2026). Biologic Therapies and Biomarkers in Severe Childhood Asthma: A Systematic Review of Omalizumab and Mepolizumab. Pediatric Pulmonology, 61(8). https://doi.org/10.1002/ppul.71756

Vancouver

Gusmão ABF, Marques BO, Gusmão ALF, de Lacerda RT, França APD, Silva EKD, et al. Biologic Therapies and Biomarkers in Severe Childhood Asthma: A Systematic Review of Omalizumab and Mepolizumab. Pediatric Pulmonology. 2026;61(8). doi:10.1002/ppul.71756

BibTeX
@article{Gusmo2026,
  author = {Gusmão, Ana Beatriz Ferreira and Marques, Breno Oliveira and Gusmão, Ana Luiza Ferreira and de Lacerda, Raquel Teles and França, Ananda Pereira da and Silva, Ellen Karoline da and Sousa, Gabrielle Silva and Pereira, Maxuell Nunes},
  title = {Biologic Therapies and Biomarkers in Severe Childhood Asthma: A Systematic Review of Omalizumab and Mepolizumab},
  journal = {Pediatric Pulmonology},
  year = {2026},
  volume = {61},
  number = {8},
  doi = {10.1002/ppul.71756}
}
Kostenlos starten →